Accordingly, the US Federal Drug Administration has approved several TKIs and mAbs as anti-EGFR treatment for advanced NSCLC patients with the EGFR-activating mutation and for mCRC patients with wild-type KRAS, but not for NSCLC patients with wild-type EGFR or CRC patients with mutant KRAS [4, 5]. Here, KRAS is linked to colorectal carcinoma.